FinscoFinsco

Bicara Therapeutics (US.BCAX)

Capital Allocation Audit · Period: 2022 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BCAX · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.2%→
ROE-10.9%↓
Cash Conversion-→
D/E Ratio0.00↓
Gross Margin-→
US.BCAX (Bicara Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.2%    →
ROE              -10.9%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↓
Gross Margin          -    →
Key Metrics
US.BCAX (Bicara Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.2% →
ROE -10.9% ↓
Cash Conversion - →
D/E Ratio 0.00 ↓
Gross Margin - →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies